Currently under construction...
Forschung/Research
Our mission is primarily to decode non-coding (genomic) alterations in the context of development, maladaptation and age-associated diseases such as cancer, cardiovascular diseases, and neurodegenerative disorders (Danckwardt et al. EMBO J. 2008, Danckwardt et al. Mol Med. 2013, Khan & Danckwardt, Genes. 2022, Danckwardt et al. Cardiovasc Res. 2023).
Our vision is to drive the development of new diagnostic concepts and lay the foundation for future therapeutic strategies.
Our strategy revolves around the use of innovative tools. We design and implement new technologies to decipher non-coding disease drivers (Danckwardt et al. Blood 2022, Danckwardt et al. Blood 2004, Danckwardt et al. EMBO J 2007, Danckwardt et al. Mol Cell, 2011, Kargapolova et al. Nucl Acid Res. 2017), enhance diagnostics, predict disease trajectories (Ogorodnikov et al. Nature Commun. 2017, Nourse & Danckwardt, J Thromb Haemost. 2023), and develop novel therapeutic strategies (Nourse et al. J Thromb Haemost. 2018, Nourse & Danckwardt, Pharmacol Therap. 2021).
A central component of our work involves non-invasive molecular imaging (Optical Imaging), high-throughput sequencing, and omics technologies (sCLIP, TRENDseq, miTRAP). Additionally, we are committed to developing research resources, including specialized FAIR-compliant databases (TREND-DB).
Based on our research, awarded with the Hella-Bühler-Award for Cancer Research, we have launched the DFG-funded Preclinical in vivo Imaging Plattform and the BMBF-funded Advanced Diagnostics Plattform. These platforms aim to make biological processes in living organisms visible and to address the pathogenetic relevance of disorders in areas such as vascular medicine, oncology, and immunology in a non-invasive manner (Steven et al. Br J Pharmacol. 2017, Schaupp et al. Cell. 2020, Nourse et al. BioRxiv. 2021). This includes tempospatial visualization of gene expression, protein secretion, ligand-receptor- and cell-cell interactions, which is also utilized for high-throughput screening of novel therapeutic approaches (patent pending).
We are actively involved in the BMBF-funded Translational Research Center for Thrombosis and Hemostasis (CTH) and the EU Horizon 2020-supported Innovative Training Network “Thromboinflammation in Cardiovascular Diseases” (TICARDIO), and part of the Center for Healthy Aging (CHA). We maintain research collaborations in national and international consortia, focusing on RNA regulation and its impact on "Health and Disease”. Notable examples include the DFG Priority Program SPP 1935 "Deciphering the mRNP Code”, with projects on transcriptomic diversity and neuronal development, the DFG Research Training Group on “R-loop Regulation in Robustness and Resilience", or our activities in the context of the ISTH GenOMICs in Thrombosis & Hemostasis SSC.
Funding
